Utolsó frissítés :
19/11/2024
Fájdalomcsillapító   Sufentanil citrate  
Injekció
Az oldatok stabilitása A keverékek stabilitása Stabilitást befolyásoló tényezők Kompatibilitás Az alkalmazás módja Irodalom pdf
   Kémiai szerkezet   

Kereskedelmi név   Kereskedelmi név     

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Fentatienil Olaszország
Sudolfen Colombia
Sufenta Amerikai Egyesült Államok, Ausztria, Belgium, Chile, Dánia, Dél-Afrikai Köztársaság, Finnország, Franciaország, Hollandia, Irán, Izland, Kanada, Lengyelország, Luxemburg, Malaysia, Németország, Norvégia, Portugália, Svájc, Svédország, Szaúd-Arábiában, Törökország, Tunézia
Zuftil Mexikó
Irodalom   Injekció   Irodalom : Sufentanil citrate  
Type publikáció
59 Napló Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
299 Napló Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Napló Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
319 Napló Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
509 Napló Roos PJ, Glerum JH, Meilink JW, Zwang L.
Effect of pH absorption of sufentanil citrate in a portable pump reservoir during storage and administration under simulated epidural conditions.
Pharm World Sci 1993 ; 15: 139-144.
510 Napló Roos PJ, Glerum JH, Schroeders MJH.
Effect of glucose 5% solution and bupivacaine hydrochloride on absorption of sufentanil citrate in a portable pump reservoir during storage and simulated infusion by an epidural catheter.
Pharm World Sci 1993 ; 15: 269-275.
675 Napló Roos PJ, Glerum JH, Meilink JW.
Stability of sufentanil citrate in a portable pump reservoir, a glass container and a polyethylene container.
Pharm Weekbl [Sci] 1992 ; 14: 196-200.
921 Napló Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1491 Napló Brouwers JRBJ, van Doorne H, Meevis RF, Boersma FP.
Stability of sufentanil citrate and sufentanil citrate/bupivacaine mixture in portable infusion pump reservoirs.
Eur Hosp Pharm 1995 ; 1: 12-14.
1508 Napló Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1516 Laboratórium Ropivacaine (Naropeine®) - Summary of Product Characteristics
Mercury Pharmaceuticals Limited 2012
1625 Napló Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1665 Napló Öster Svedberg K, McKenzie J, Larrivee-Elkins C.
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine.
J Clin Pharm Ther 2002 ; 21: 39-45.
1712 Napló Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Napló Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Napló Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1752 Napló Jäppinen AL, Hokki H, Rasi AS, Naaranlathi TJ.
Stability of sufentanil in a syringe pump under simulated epidural infusion.
Int J Pharm Compound 1998 ; 2: 466-468.
1759 Napló Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803 Napló Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1835 Napló Jäppinen A, Turpeinen M, Kokki H, ,Rasi A, Ojanen T, Pelkonen O, Naaranlahti T.
Stability of sufentanil and levobupivacain solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes.
Eur J Pharm Sci 2003 ; 19, 1: 31-36.
1882 Napló Bosch EH, Van Doorne H, Brouwers JRBJ, Marskamp A, Meevis RF.
Decrease of sufentanil citrate concentration during formulation and application of an epidural infusion solution.
Ziekenhuisfarmacie 1993 ; 9: 97-101.
1908 Napló Boitquin L, Hecq JD, Evrard JM, Vanbeckbergen D, Jamart J, Galanti L.
Long-term stability of sufentanil citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion PVC bags at 4°C.
J Pain Symptom Manage 2004 ; 28, 1: 4-6.
1909 Napló Farhang-Asnefi S, Barre J, Callaert S, Boutros A, Causse R, Thebault A.
Compatibilité et stabilité du mélange bupivacaïne-sufentanil en poche.
J Pharm Clin 2000 ; 19: 248-251.
1925 Napló Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1938 Napló Boitquin LP, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM.
Stability of sufentanil citrate with levobupivacaine hydrochloride in NaCl 0.9% after microwave freeze-thaw treatment.
Ann Pharmacotherapy 2004 ; 38: 1836-1839.
1962 Napló Hecq JD, Boitquin L, Evrard JM, Vanbeckbergen D, Jamart J, Galanti L.
Long term stability of sufentanyl citrate with levobupivacaine hydrochloride in 0.9% sodium chloride infusion P.V.C bags at 4°C.
Pharmakon 2004 ; 36, 1: 8-14.
2118 Napló Chapalain-Pargade S, Laville I, Paci A, Chachaty E, Mercier L, Bourget Ph.
Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery-systems.
J Pain Symptom Manage 2006 ; 32, 1: 90-97.
2119 Napló Westphal M, Hohage H, Buerckle H, Van Aken H, Ermert T, Brodner G.
Adsorption of sufentanil to epidural filters and catheters.
Eur J Anaesthesiol 2003 ; 20: 124-126.
2138 Napló Brodner G, Ermert T, Van Aken H et al.
Stability of a sufentanil-ropivacaine mixture in a glass and a PVC reservoir.
Eur J Anaesthesiol 2002 ; 19: 295-297.
2141 Napló Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2146 Napló Trissel LA, Xu QA, Baker M.
Drug compatibility with new polyolefin infusion solution containers.
Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2196 Napló Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2231 Napló de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2280 Napló Shields DE, Aclan J, Szatkowski A.
Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration.
Int J Pharm Compound 2008 ; 12, 5: 463-466.
2319 Napló Janssen K, Wisselo R, Geerlings C, Schouten J.P.
Chemical stability of a solution of bupivacaine hydrochloride 0.125% and sufentanil citrate 0.5 µg/ml for filling syringes using a repeater pump.
EJHP Science 2009 ; 15, 1: 11-14.
3012 Napló Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3294 Napló Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
EJHP 2012 ; 19: 57-64.
3380 Napló Eckle V-S, Heim E, Hahn M, Grasshoff C.
Incompatibility of Piritramide with Cephalosporins.
Ann Pharmacotherapy 2013 ;47:426-427.
3385 Napló Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408 Napló Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3504 Laboratórium Parecoxib (Dynastat®) - Summary of Product Characteristics
Pfizer 2012
3601 Laboratórium Cisatracurium Actavis - Résumé des Caractéristiques du Produit
Actavis 2012
3644 Laboratórium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3705 Napló Knudsen L, Eisend S, Haake N, Kunze T.
Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine.
EJHP 2014 ;21:161-166
3824 Napló Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3964 Napló Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4011 Napló Gersonde F, Eisend S, Haake N, Kunze T.
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
EJHP 2016 2016;0:1-11
4080 Napló Zbytovska J, Gallusova J, Vidlarova L, Prochazkova K, Simek J, Stepanek F.
Physical Compatibility of Propofol-Sufentanil Mixtures.
Anaesthesia 2017 ;124,3:776-781
4162 Napló Sorrieul J, Robert J, Gibory V, Kieffer H, Folliard C, Dupoiron D, Devys C.
Stability of sufentanil and baclofen mixtures for intrathecal analgesia at different concentrations in polypropylene syringes.
Ann Pharm Fr 2018 ;76,6:444-452
4319 Napló Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 Napló Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4496 Napló Sorrieul J, Robert J, Dupoiron D, Devys, C.
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.
Neuromodulation 2020 ; 24, 7: 1145-1156.
4522 Napló Lin Q, Van Schepdael A, Adams E.
Six months stability investigation of sufentanil and ropivacaine/levobupivacaine admixtures in plastic container by LC-UV.
J Pharm Biomed Anal 2020
4742 Napló Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales